Gallery — Recent

This a template based on papers package, modified by me.

Modelo de relatório de estágio DAS - UFSC. Contribua em github.com/gabrielpra1/relatorio-estagio-das

We would like to focus on a popular macroeconomics problem called Utility Maximization, where the goal is to maximize the happiness of a consumer.

This template gives a basic introduction to \(\mathrm{\LaTeX}\) and provides a template for the Creighton University Master's thesis, especially as pertains to the MS in physics and medical physics degrees.

A slight modification to the report template provided by TU/e LaTeX package. Next version to be released soon.

高校数学～大学基礎レベルの数学の問題集（解答付き） Simple math problem set with solution.

Credits to original author who shared it on Sharelatex.

This utmthesis class was first created back in 2006. Since then, thanks to the various contributors over the years, it has matured into this. List of major contributors (sorted alphabetically) Lim Lian Tze Loo Hui Ru Muhammad Nadzir Marsono Ng Choon Ching Teo Hui Ming Vishnu P. Nambiar Yap Yung Szen Wan Zuki Azman credits also to other contributors/testers whose names are not listed here UTMthesis.cls v6.4 (2021/05/02) conforms with the 2018 UTM thesis manual.

Chronic Myeloid Leukemia is a type of cancer that starts in certain blood-forming cells of the bone marrow. Interferon-\(\alpha\) was once the standard front-line treatment producing remission rates of only 28.3 percent in 1991. After the highly effective drugs first became available in 2001, survival rates have increased immensely. According to the American Cancer Society, one large study of CML patients treated with a drug called imatinib found that about 90 percent of them were still alive 5 years after starting treatment. While imatinib has changed the way oncologists treat CML, remission is common after extended gaps in treatment. In this paper, we will explore the long-term dynamics of CML under treatment through the use of use of theoretical and mathematical components. We closely base our methods upon the approach of Urszula Ledzewicz and Helen Moore. We will introduce our unique model and explain component selections, while we move towards understanding the optimal interactions of imatinib and interferon-\(\alpha\) against dormant and proliferating CML cells. Our future work involving optimal control dynamics will be briefly introduced and further solutions are currently ongoing.